Nearly three times as many reached remission: fresh hope for Crohn's patients facing its toughest complication

For people living with Crohn's disease, one complication can take over daily life: fistulas — small, painful tunnels that form around the bowel and refuse to close. In the FUZION study, the first trial of its kind in more than 20 years, Johnson & Johnson's medicine TREMFYA (guselkumab) helped 27–28% of patients reach full remission of those fistulas after 24 weeks, compared with 10% on a placebo. New analyses shared at a major digestive-health meeting in Nashville show the benefit held in every hard-to-treat group doctors checked — people whose disease was most active, people who had already tried other advanced medicines, and people with inflammation nearby. Side effects matched what doctors already know about the medicine. For patients who have cycled through option after option, consistency like this is its own kind of good news.